FindTrial
Sign In

Evaluation of efficacy and safety of autologous bone marrow mesenchymal stem cells for traumatic spinal cord injury: Use-results comparative survey

Evaluation of efficacy and safety of autologous bone marrow mesenchymal stem cells for traumatic spinal cord injury: Use-results comparative survey

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2053210130
Enrollment
612
Registered
2021-12-10
Start date
2019-05-16
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury

Interventions

Intravenous infusion of autologous mesenchymal stem cells derived from bone marrow

Sponsors

Room Stemirac Information
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients using autologous mesenchymal stem cells derived from bone marrow for the first time for traumatic spinal cord injury (2) Patients or their surrogates must provide informed consent before the start

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
Cohort 1: Percentage of the case with 2 or more levels of AIS improvement from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury in AIS A patients aged 20 to 70 years with traumatic cervial spinal cord injury Cohort 2: Percentage of the case with 1 or more levels of AIS improvement from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury in AIS B or C patients aged 20 to 70 years with traumatic cervial spinal cord injury—

Contacts

Public ContactStemirac Information Room

NIPRO CORPORATION

saisei-clinicalstudy-information@nipro.co.jp+81-120-002-192

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026